Suggestions
Eric Kelsic
CEO Dyno Therapeutics - AAV gene therapy - We are Hiring!
Eric Kelsic is a renowned figure in the field of gene therapy, focusing on AAV capsid engineering and the application of artificial intelligence and machine learning techniques. He is associated with Dyno, a company at the forefront of utilizing advanced technologies to enhance gene therapy outcomes. Eric Kelsic's areas of interest span AAV Gene Therapy, High-throughput Synthetic Biology, Machine Learning, Software Engineering, and Alliance Management.
With an impressive educational background, Eric Kelsic holds a Doctor of Philosophy (PhD) in Systems Biology from Harvard University and a Bachelor of Science (BS) in Physics from Caltech.
Throughout his career, Eric Kelsic has held various key roles including Founder & CEO at Dyno Therapeutics, Staff Scientist at the Lab of George Church at Wyss Institute for Biologically Inspired Engineering, Postdoctoral Research Fellow at the Lab of George Church at Harvard Medical School, Graduate Student at the Lab of Roy Kishony at Harvard University, English Instructor at Nankai University, Researcher and Technician in Chemical Engineering at the Smolke Lab at Caltech, Summer Undergraduate Research Fellow at Caltech with Mason Porter, Summer Undergraduate Research Fellow at the National Institute of Standards and Technology, and Summer Undergraduate Research Fellow at the Atwater Lab at Caltech. Eric Kelsic also dabbled in entrepreneurial ventures, being a Puzzle Box Inventor at his own company.
Eric Kelsic's expertise lies in the intersection of gene therapy, artificial intelligence, machine learning, and biotechnology. His contributions to the field have been significant, and his diverse experiences in academia, research, and industry have shaped his unique perspective on the integration of cutting-edge technologies in biomedicine.
Highlights
Looking forward to speaking at the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston), focused on innovating gene therapy capsid and payload design. I will be presenting on Dyno’s latest breakthroughs enabling machine-guided design of AAV capsids for ocular and CNS indications. For more info see https://ter.li/oz9aqf or contact Nick Mayne, Program Director for the event.
Great turnout of AAViators representing Dyno Therapeutics at this year’s #ASGCT Annual Meeting. The #AAV field is growing and moving fast, but we’re focused on learning how to make better gene therapies to help patients. Happy to reconnect with so many friends and colleagues at the meeting, every year this is such an inspiring event for me.
